Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Shares of Seagen Inc. SGEN, +3.22% were up 2.4% in trading on Monday after the company said its president and CEO Clay Siegall has resigned. Seagen had announced last week that Siegall would take a leave of absence after he was allegedly involved in a domestic violence incident at his home.

Seagen says CEO has resigned

Alphabet

Buying these stocks on the dip could result in big returns for investors.

2 Cheap Growth Stocks Near Their 52-Week Lows to Buy and Forget

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen's Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found. The Board had previously announced that Dr. Siegall

Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

Biohaven Pharmaceutical Hld

FibroGen

Intra-Cellular Therapies

Should investors pay more attention to these biotech stocks?

What Stocks To Buy This Week? 4 Biotech Stocks To Know

Clay Siegall, the CEO, president, and chairman of Bothell, Wash.

Seagen CEO takes leave of absence amid domestic violence allegations, shares down 8%

Seagen is a phenomenal innovation success story that delivers hope to patients afflicted by deadly cancers while also rewarding shareholders. The approved therapeutics should generate at least $1.6B in revenue this year. Due to various ongoing label expansions, you can expect a much stronger top-line growth rate.

Seagen: Brewing Blockbusters

BOTHELL, Wash.--(BUSINESS WIRE)--The Board of Directors of Seagen Inc. (Nasdaq: SGEN) today announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence. The company is aware of an alleged incident of domestic violence that occurred recently at Dr. Siegall's home. Dr. Siegall has denied these allegations and has informed the company that he is engaged in a divorce. The Board of Directors has formed a committee of independent directors and is conducting a thorough inve

Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence

Moderna

Ngm Biopharmaceuticals Inc

Regeneron Pharmaceuticals

TG Therapeutics

After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.

5 Graham's Lost Formula Biotech Stocks to Consider for May

Incyte

Novo Nordisk

Which biotech stocks do you have on your May 2022 watchlist?

3 Top Biotech Stocks To Watch In May 2022

Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.

Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates

Seagen Inc. (NASDAQ:SGEN ) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Peggy Pinkston - Senior Vice President of Investor Relations Clay Siegall - President & Chief Executive Officer Todd Simpson - Chief Financial Officer Chip Romp - Executive Vice President, Commercial U.S. Roger Dansey - Chief Medical Officer Conference Call Participants Cory Kasimov - JPMorgan Salveen Richter - Goldman Sachs Andrew Berens - SVB Michael Schmidt - Guggenheim Gena Wang - Barclays Andy Hsieh - William Blair Jay Olson - Oppenheimer Reni Benjamin - JMP Securities Zhiqiang Shu - Berenberg Joe Catanzaro - Piper Sandler Operator Good day, and welcome to the Seagen First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

Seagen Inc. (SGEN) CEO Clay Siegall on Q1 2022 Results - Earnings Call Transcript

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 24.49% and 4.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q1 Loss, Tops Revenue Estimates

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) reported financial results today for the first quarter ended March 31, 2022. The Company also highlighted PADCEV® (enfortumab vedotin-ejfv), TUKYSA® (tucatinib), ADCETRIS® (brentuximab vedotin) and TIVDAK® (tisotumab vedotin-tftv) commercial and development accomplishments, as well as progress across its deep and diverse oncology pipeline. “Seagen delivered strong results for the first quarter of 2022 with net product sales increasing 2

Seagen Reports First Quarter 2022 Financial Results

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its expanding pipeline of marketed and investigational therapies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 in Chicago. The accepted abstracts demonstrate the growth of Seagen's portfolio and clinical progress across multiple cancer types, including cervical and urothelial cancers and pediatric and adult Hodgkin lymphoma. Grou

Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Seagen is expanding its manufacturing capacity in the Seattle area.

Biotech giant Seagen reveals plans for 270K square-foot manufacturing facility near Seattle

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced plans to build a new facility in Everett, Washington, to expand the company's biomanufacturing capacity and enable the company greater control and flexibility over the production of its medicines to treat cancer. The 270,000-square-foot facility will be built north of the company's U.S. headquarters in Bothell, Washington. Seagen expects to have the facility operational in 2024 and ultimately employ up to 200 highly ski

Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines

The European Commission approves Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

Seagen (SGEN) Gets Nod From EU for Bladder Cancer Drug, Padcev

- Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor - TOKYO and BOTHELL, Wash. , April 13, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.

European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer

Alibaba

New Fortress Energy

Snap

Tellurian

We've crunched the data to bring you the best and boldest Top Stocks from last week's winners and losers.

Top Stocks To Buy This Week

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that a jury in the U.S. District Court for the Eastern District of Texas found that Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) infringed Seagen's U.S. Patent No. 10,808,039 by selling in the United States its Enhertu® product (trastuzumab deruxtecan; DS-8201). Seagen was awarded damages of $41.82 million for past infringement of the patent. In addition, Seagen will request additional royalty payments for future sales of

Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced data from intravesical instillation of enfortumab vedotin (EV) in a non-muscle invasive bladder cancer (NMIBC) preclinical model in addition to preclinical data from SGN-ALPV and SGN-B7H4V, two of its novel antibody-drug conjugates (ADCs) that utilize the company's proprietary vedotin drug linker technology. These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place

Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced that it will report its first quarter 2022 financial results on Thursday, April 28, 2022 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. Conference call and webcast information: Telephone 844-763-8274 (U.S.) or +1 412-717-9224 (international); conference ID 101

Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022

CRISPR Therapeutics

Etsy

Lockheed Martin

MP Materials

Micron Technology

Upstart Holdings

YUM! Brands

Some of these stocks present long opportunities as they pull back.

9 Wave Setups To Watch (Video)

Sanofi

Seagen (SGEN) inks a collaboration agreement with Sanofi to develop and commercialize antibody-drug conjugates for three cancer targets.

Seagen (SGEN) Inks ADC Deal With Sanofi for Cancer Targets

BOTHELL, Wash. & PARIS--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) and Sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and Sanofi currently has

News for Seagen Stock (SGEN)